Date: 2013-02-12
Type of information:
Compound: identification of genetic mutations in cancer patients
Company: AstraZeneca (UK) Petrov Institute of Oncology (Russia)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: AstraZeneca and the N.N. Petrov Institute of Oncology, one of Russia’s leading cancer research institutions, have announced a research collaboration to identify genetic mutations in cancer patients. The agreement, among the first of its kind between a global biopharmaceutical company and a Russian research centre, was signed during a ceremony in St. Petersburg, Russia.Establishing the role these genetic mutations play in the growth and spread of certain types of cancer may lead to the development of better therapies, improvements in disease management and innovative approaches to personalized healthcare for patients worldwide. Personalized healthcare is a core capability within AstraZeneca R&D and a priority within the Russian government’s Healthcare Development 2020 programme.
Under the terms of the agreement, Petrov Institute scientists will work in collaboration with teams from AstraZeneca’s Oncology Innovative Medicines group at centres worldwide, providing a framework that brings together complimentary skills to harness and foster medical innovation: the Petrov Institute via its research infrastructure and scientific expertise in St. Petersburg, Russia and AstraZeneca via its proven track record in global research and discovery in oncology.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
